Individual applicator for brachytherapy for various sites of superficial malignant lesions

Kowalik, Łukasz; Łyczek, Jarosław; Sawicki, Marcin; Kazalski, Damian

doi:10.5114/jcb.2013.34340

Cited by 26 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, during HDR-BT, the dose remains on the surface and does not penetrate deeply with optimal sparing of normal tissues due to dose concentration into the clinical target volumes (CTV) and rapid dose fall-off at target periphery [10, 11, 12, 13, 14, 15, 16, 17]. Published studies have mainly reported standard fractionation and hypofractionated brachytherapy regimens in patients treated with HDR-BT, and the biological effective dose (BED) was often calculated due to define the total dose and dose for fractions regimen for a better local control and acceptable late and acute toxicity [19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37].…”

Section: Resultsmentioning

confidence: 99%

“…Compared to the other radiotherapy technique, HDR-BT might be a better therapeutic option due to essential advantages such as high radiation dose concentration into the clinical target volumes (CTV), rapid dose fall-off at target periphery, optimal sparing of normal tissues in sensitive structures, shorter treatment time, and the use of hypofractionated course [11, 12, 13, 14, 15, 16, 17]. …”

Section: Purposementioning

confidence: 99%

See 1 more Smart Citation

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Delishaj¹,

Rembielak²,

Manfredi³

et al. 2016

jcb

View full text Add to dashboard Cite

PurposeThe incidence of non-melanoma skin cancer (NMSC) has been increasing over the past 30 years. There are different treatment options and surgical excision is the most frequent treatment due to its low rates of recurrence. Radiotherapy is an effective alternative of surgery, and brachytherapy (BT) might be a better therapeutic option due to high radiation dose concentration to the tumor with rapid dose fall-off resulting in normal tissues sparing. The aim of this review was to evaluate the local control, toxicity, and cosmetic outcomes in NMSC treated with high-dose-rate BT (HDR-BT).Material and methodsIn May 2016, a systematic search of bibliographic database of PubMed, Web of Science, Scopus, and Cochrane Library with a combination of key words of “skin cancer”, “high dose rate brachytherapy”, “squamous cell carcinoma”, “basal cell carcinoma”, and “non melanoma skin cancer“ was performed. In this systematic review, we included randomized trials, non-randomized trials, prospective and retrospective studies in patients affected by NMSC treated with HDR-BT.ResultsOur searches generated a total of 85 results, and through a process of screening, 10 publications were selected for the review. Brachytherapy was well tolerated with acceptable toxicity and high local control rates (median: 97%). Cosmetic outcome was reported in seven study and consisted in an excellent and good cosmetic results in 94.8% of cases.ConclusionsBased on the review data, we can conclude that the treatment of NMSC with HDR-BT is effective with excellent and good cosmetics results, even in elderly patients. The hypofractionated course appears effective with very good local disease control. More data with large-scale randomized controlled trials are needed to assess the efficacy and safety of brachytherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Purposementioning

confidence: 99%

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Delishaj¹,

Rembielak²,

Manfredi³

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…To re-emphasise, brachytherapy techniques seem to be the most effective and easy treatment to protect organs located deeper than 2 cm below the surface, and from the perspective of protecting critical healthy organs as well. However, it demands technical expertise in these cases [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Postoperative interstitial brachytherapy in eyelid cancer: long term results and assessment of Cosmesis After Interstitial Brachytherapy scale

Laskar

Basu

Chaukar

et al. 2014

jcb

View full text Add to dashboard Cite

PurposeTo analyse feasibility and safety of postoperative interstitial brachytherapy (IBRT) in patients of eyelid cancer treated primarily by surgical excision.Material and methodsIn this series, 8 patients with eyelid cancer were treated using postoperative interstitial brachytherapy. Patients were followed up for local control, cosmetic outcome, and acute and late toxicities. Cosmetic outcome was measured using a 6 point indigenous Cosmesis After Interstitial Brachytherapy (CAIB) scale.ResultsThe patients were between 23-82 years (median: 71 years). There were 3 females and 5 males, and 3 patients had lesions in upper eyelid. Postoperative high-dose-rate brachytherapy was used in all with 2 catheters implanted in most of them (6 out of 8). Local control was calculated from end of treatment to last follow-up. At last follow-up, all patients remained locally controlled. Two patients had nodal recurrence 6 months after interstitial brachytherapy and were salvaged effectively by external beam radiotherapy. At last follow-up, 7 patients were loco-regionally controlled and one was lost to follow up. All patients had Radiation Therapy Oncology Group (RTOG) grade 1 acute toxicity and 2 had grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version.3 late toxicities. The cosmesis score for the whole group ranged between 0-1 indicating excellent to very good cosmesis.ConclusionsPostoperative high-dose-rate brachytherapy resulted in excellent disease control and cosmesis without significant acute or late toxicities. It is an effective modality for treatment of eyelid cancers in selected patients. Future prospective studies with the validation of CAIB scale would give us more insight to this effective yet often ignored modality of IBRT.

show abstract

“…Kowalik et al . [ 23 ] described CT based HDR surface mold brachytherapy technique for three unfavorably localized malignant lesion and have described in detail the process of manufacturing individual applicator. Similarly, we in our study used CT based plan optimization.…”

Section: Discussionmentioning

confidence: 99%

Recurrent Bowen’s disease of scalp treated with high dose rate surface mold brachytherapy: a and review of the literature

Gandhi¹,

Laviraj²,

Kashyap³

et al. 2014

jcb

View full text Add to dashboard Cite

Our case is a 46-year-old female presenting to us with Bowen's disease of scalp since 5 years. Patient had failed topical therapy with 5% 5-florouracil, 0.1% tacrolimus and was intolerant to topical imiquimod. At presentation, she had 15 cm × 10 cm erythematous, hyperpigmented, crusted plaque with irregular border in the superior and lateral aspect of left side of scalp with extension in to forehead. Patient was treated with computed tomography based customized surface mold high dose rate brachytherapy with Iridium-192 to a dose of 35 Gy in 10 fractions (twice daily, 6 hours apart) over 5 days. Patient tolerated the treatment well and showed regression of the lesion with mild dermatitis at the end of treatment. Though dermatitis increased at 2 weeks, at 4 weeks post treatment there was near complete resolution of the lesion with adjacent alopecia. At 8 weeks after completion of the treatment, there was complete resolution of the lesion and patient was asymptomatic. Alopecia in the adjacent area has resolved and the skin pigmentation has begun. Patient is satisfied with both the disease control and the cosmetic outcome of the procedure. Our case report demonstrates successful application of surface mold high dose rate brachytherapy in the treatment of recurrent Bowen's disease of the scalp. Brachytherapy can play an important role in the management of recurrent malignant and premalignant diseases of the complex treatment sites like scalp and it's non-hesitant use should be encouraged in appropriately selected patients at the earliest.

show abstract

Individual applicator for brachytherapy for various sites of superficial malignant lesions

Cited by 26 publications

References 6 publications

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Postoperative interstitial brachytherapy in eyelid cancer: long term results and assessment of Cosmesis After Interstitial Brachytherapy scale

Recurrent Bowen’s disease of scalp treated with high dose rate surface mold brachytherapy: a and review of the literature

Contact Info

Product

Resources

About